Free Trial

60 Degrees Pharmaceuticals Q1 2024 Earnings Report

60 Degrees Pharmaceuticals logo
$1.86 +0.02 (+1.09%)
As of 02:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

60 Degrees Pharmaceuticals EPS Results

Actual EPS
$0.15
Consensus EPS
-$0.80
Beat/Miss
Beat by +$0.95
One Year Ago EPS
N/A

60 Degrees Pharmaceuticals Revenue Results

Actual Revenue
$0.08 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

60 Degrees Pharmaceuticals Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Remove Ads

60 Degrees Pharmaceuticals Earnings Headlines

Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
60 Degrees Pharmaceuticals announces 1-for-5 reverse stock split
60 Degrees says FDA does not object to tafenoquine import plan
See More 60 Degrees Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 60 Degrees Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 60 Degrees Pharmaceuticals and other key companies, straight to your email.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals (NASDAQ:SXTP), a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

View 60 Degrees Pharmaceuticals Profile

More Earnings Resources from MarketBeat